These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32667156)

  • 1. Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes.
    Preiser JC; Provenzano B; Mongkolpun W; Halenarova K; Cnop M
    Anesthesiology; 2020 Aug; 133(2):430-438. PubMed ID: 32667156
    [No Abstract]   [Full Text] [Related]  

  • 2. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract]   [Full Text] [Related]  

  • 3. Jentadueto XR for type 2 diabetes.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):98-100. PubMed ID: 27466749
    [No Abstract]   [Full Text] [Related]  

  • 4. [Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes].
    Hayashi A; Kubo T; Okuyama K; Tokita S; Kamei M
    Yakugaku Zasshi; 2019; 139(12):1569-1581. PubMed ID: 31787647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 6. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
    Hermans M; Van Gaal L; Rézette I; Daci E; MacDonald K; Denhaerynck K; Vancayzeele S; De Meester L; Clemens A; Yee B; Abraham I
    Prim Care Diabetes; 2016 Dec; 10(6):425-433. PubMed ID: 27388795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What role will 'gliptins' play in glycemic control?
    Bloomgarden Z; Drexler A
    Cleve Clin J Med; 2008 Apr; 75(4):305-10. PubMed ID: 18491437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 11. A survey: perioperative diabetes medications and glucose control-time to re-examine management?
    Brown R; Siddiqui U; Paul J
    Can J Anaesth; 2019 May; 66(5):621-622. PubMed ID: 30726550
    [No Abstract]   [Full Text] [Related]  

  • 12. Response letter to D. Singh-franco et al.
    Owens DR; Del Prato S; Taskinen MR; Gomis R; Forst T; Woerle HJ
    Diabetes Obes Metab; 2012 Nov; 14(11):1054-5. PubMed ID: 23034010
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].
    Granata A; Insalaco M; Di Nicolò P; Scarfia VR; Russo L; D'anna G; Lentini P; Fiorini F; Fatuzzo P
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes].
    Carramiñana Barrera FC
    Semergen; 2018 Jun; 44 Suppl 1():10-17. PubMed ID: 30322468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical markers associated with glycaemic response to dipeptidyl peptidase-4 inhibitor therapy.
    Yamagishi SI
    Diabetes Metab Res Rev; 2018 Oct; 34(7):e3024. PubMed ID: 29763999
    [No Abstract]   [Full Text] [Related]  

  • 17. [Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents].
    Mori Y
    Nihon Rinsho; 2011 Aug; 69(8):1505-14. PubMed ID: 21838054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
    Seguí Díaz M
    Semergen; 2018 Jun; 44 Suppl 1():18-25. PubMed ID: 30322469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel combined glucose-lowering drug with DPP-4 inhibitor and pioglitazone].
    Fujita Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():642-6. PubMed ID: 22768591
    [No Abstract]   [Full Text] [Related]  

  • 20. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.